ENTX · XBRL financial data

Entera Bio financial statements, every fiscal year

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ENTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	365	571	134	0	181	42
Cost of revenue	300	373	101	0	172	42
Gross profit	65	198	33	0	9	0
Research and development	6,382	6,771	5,848	4,510	4,499	6,004
Selling, general and administrative	—	—	—	—	340	398
General and administrative	4,851	5,690	7,253	4,430	5,095	5,525
Total operating expenses	11,233	12,415	13,050	8,891	9,594	11,529
Operating income (loss)	(11,168)	(12,217)	(13,017)	(8,891)	(9,585)	(11,529)
Income tax expense (benefit)	20	(59)	137	29	14	0
Net income (loss)	(11,216)	(12,187)	(13,071)	(8,889)	(9,541)	(11,439)
Earnings per share, basic USD per share	—	0.47	0.45	0.31	0.25	0.25
Earnings per share, diluted USD per share	—	0.47	0.45	0.31	0.25	0.25
Weighted average shares, basic thousands of shares	—	26,134	28,808	29,008	37,650	46,191
Weighted average shares, diluted thousands of shares	—	26,134	28,808	29,008	37,650	46,191
Revenue	365	—	—	—	—	—
Cost of sales	209	—	—	—	—	—
Research and development	6,398	—	—	—	—	—
Operating profit (loss)	(11,133)	—	—	—	—	—
Profit (loss)	(9,983)	—	—	—	—	—
Earnings per share, basic USD per share	0.54	—	—	—	—	—
Earnings per share, diluted USD per share	0.55	—	—	—	—	—

Fiscal years (ENTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	8,593	24,892	12,309	11,019	8,660	7,108
Accounts receivable	255	183	246	0	126	0
Prepaid and other current assets	—	—	294	238	186	415
Total current assets	9,109	25,329	12,849	11,257	8,972	15,298
Property and equipment, net	192	156	139	100	57	134
Right-of-use asset	374	239	90	388	275	465
Total assets	9,722	25,987	13,127	11,765	9,390	15,993
Accounts payable	164	166	17	83	132	448
Total current liabilities	1,841	3,161	1,341	1,091	1,176	2,203
Lease liability, non-current	243	123	0	256	102	260
Total liabilities	2,212	3,422	1,373	1,379	1,310	2,892
Accumulated deficit	(70,239)	(82,426)	(95,497)	(104,386)	(113,927)	(125,366)
Total stockholders' equity	7,510	22,565	11,754	10,386	8,080	13,101
Total liabilities and equity	9,722	25,987	13,127	11,765	9,390	15,993
Common shares outstanding (cover page) thousands of shares	23,739	28,804	28,810	35,481	45,421	46,622
Cash and cash equivalents	8,593	—	—	—	—	—
Total current assets	9,109	—	—	—	—	—
Total assets	10,262	—	—	—	—	—
Total current liabilities	3,273	—	—	—	—	—
Total liabilities	3,597	—	—	—	—	—
Total equity	6,665	—	—	—	—	—
Total equity and liabilities	10,262	—	—	—	—	—

Fiscal years (ENTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(11,216)	(12,187)	(13,071)	(8,889)	(9,541)	(11,439)
Stock-based compensation	901	1,861	2,247	1,689	2,556	2,750
Net cash from operating activities	(10,557)	(9,063)	(12,499)	(7,310)	(6,818)	(7,370)
Purchases of property and equipment	53	17	47	17	3	107
Net cash from investing activities	(53)	(17)	(102)	(17)	(3)	(107)
Proceeds from issuing common stock	3,187	21,805	0	5	3,960	6,254
Net cash from financing activities	4,051	25,381	13	6,036	4,476	13,710
Net change in cash	(6,559)	16,301	(12,588)	(1,291)	(2,345)	6,197
Net cash from operating activities	(10,423)	—	—	—	—	—
Net cash from investing activities	(86)	—	—	—	—	—
Net cash from financing activities	3,917	—	—	—	—	—

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Entera Bio	11,309	0	(3,464)*	173.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Anixa Biosciences	1,398	not reported	(1,770)*	34.8M	6.8 quarters	Q3 FY26 10-QJul 31, 2026
Immunic	155,098	not reported	(30,998)*	13.6M	5.0 quarters	Q2 FY26 10-QJun 30, 2026
Filana Therapeutics	46,990	not reported	(6,094)*	50.3M	7.5 quarters	Q3 FY26 10-QSep 30, 2026
Coherus Oncology	82,923	not reported	(62,090)*	154.5M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Elicio Therapeutics	30,900	not reported	(10,364)*	28.3M	3.1 quarters	Q3 FY26 10-QSep 30, 2026
GENELUX	9,184	not reported	(6,444)*	45.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Oramed Pharmaceuticals	15,245	not reported	(200)*	41.6M	189.8 quarters	Q2 FY26 10-QJun 30, 2026
XBiotech	109,528	not reported	(4,515)*	30.5M	24.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 3:27 PM ET. The filing on SEC.gov is the record.